Effect of nocturnal oxygen and acetazolamide on exercise performance in patients with pre-capillary pulmonary hypertension and sleep-disturbed breathing: randomized, double-blind, cross-over trial
- PMID: 24366914
- DOI: 10.1093/eurheartj/eht540
Effect of nocturnal oxygen and acetazolamide on exercise performance in patients with pre-capillary pulmonary hypertension and sleep-disturbed breathing: randomized, double-blind, cross-over trial
Abstract
Aim: Sleep-disturbed breathing (SDB) is common in pre-capillary pulmonary hypertension (PH) and impairs daytime performance. In lack of proven effective treatments, we tested whether nocturnal oxygen therapy (NOT) or acetazolamide improve exercise performance and quality of life in patients with pre-capillary PH and SDB.
Methods: This was a randomized, placebo-controlled, double-blind, three period cross-over trial. Participants received NOT (3 L/min), acetazolamide tablets (2 × 250 mg), and sham-NOT/placebo tablets each during 1 week with 1-week washout between treatment periods. Twenty-three patients, 16 with pulmonary arterial PH, 7 with chronic thromboembolic PH, and with SDB defined as mean nocturnal oxygen saturation <90% or oxygen saturation dips >10 h(-1) with daytime PaO2 ≥7.3 kPa participated. Assessments at the end of the treatment periods included a 6 min walk distance (MWD), SF-36 quality of life, polysomnography, and echocardiography.
Results: Medians (quartiles) of the 6 MWD after NOT, acetazolamide, and placebo were 480 m (390;528), 440 m (368;468), and 454 m (367;510), respectively, mean differences: NOT vs. placebo +25 m (95% CI 3-46, P= 0.027), acetazolamide vs. placebo -9 m (-34-17, P = 0.223), and NOT vs. acetazolamide +33 (12-45, P < 0.001). SF-36 quality of life was similar with all treatments. Nocturnal oxygen saturation significantly improved with both NOT and acetazolamide. Right ventricular fractional area change was greater on NOT compared with placebo (P = 0.042) and acetazolamide (P = 0.027).
Conclusions: In patients with pre-capillary PH and SDB on optimized pharmacological therapy, NOT improved the 6 MWD compared with placebo already after 1 week along with improvements in SDB and haemodynamics.
Clinicaltrialsgov: NTC01427192.
Trial registration: ClinicalTrials.gov NCT01427192.
Keywords: Hypertension; Hypoxia; Pulmonary; Pulmonary heart disease; Sleep.
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2013. For permissions please email: journals.permissions@oup.com.
Similar articles
-
Effect of oxygen and acetazolamide on nocturnal cardiac conduction, repolarization, and arrhythmias in precapillary pulmonary hypertension and sleep-disturbed breathing.Chest. 2014 Nov;146(5):1226-1236. doi: 10.1378/chest.14-0495. Chest. 2014. PMID: 24991933 Clinical Trial.
-
Patients with obstructive sleep apnea syndrome benefit from acetazolamide during an altitude sojourn: a randomized, placebo-controlled, double-blind trial.Chest. 2012 Jan;141(1):131-138. doi: 10.1378/chest.11-0375. Epub 2011 Jun 9. Chest. 2012. PMID: 21659435 Clinical Trial.
-
Effect of 5 weeks of oral acetazolamide on patients with pulmonary vascular disease: A randomized, double-blind, cross-over trial.Pulmonology. 2024 Jul-Aug;30(4):362-369. doi: 10.1016/j.pulmoe.2022.11.004. Epub 2023 Jan 11. Pulmonology. 2024. PMID: 36639329 Clinical Trial.
-
Precapillary Pulmonary Hypertension and Sleep-Disordered Breathing: Is There a Link?Respiration. 2017;93(1):65-77. doi: 10.1159/000452957. Epub 2016 Nov 25. Respiration. 2017. PMID: 27884004 Review.
-
[Pulmonary artery hypertension and nocturnal hypoxemia in chronic obstructive bronchopneumopathy].Rev Mal Respir. 1991;8(1):13-27. Rev Mal Respir. 1991. PMID: 2034851 Review. French.
Cited by
-
Characteristics and risk profiles of patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension living permanently at >2500 m of high altitude in Ecuador.Pulm Circ. 2024 Jul 5;14(3):e12404. doi: 10.1002/pul2.12404. eCollection 2024 Jul. Pulm Circ. 2024. PMID: 38974936 Free PMC article.
-
Effect of nocturnal oxygen therapy on exercise performance of COPD patients at 2048 m: data from a randomized clinical trial.Sci Rep. 2021 Oct 13;11(1):20355. doi: 10.1038/s41598-021-98395-w. Sci Rep. 2021. PMID: 34645842 Free PMC article. Clinical Trial.
-
Effects of oxygen therapy in a pediatric normoxemic patient with pulmonary arterial hypertension and congenital heart disease.Pulm Circ. 2019 Apr-Jun;9(2):11772045894019845610. doi: 10.1177/2045894019845610. Pulm Circ. 2019. PMID: 30942130 Free PMC article.
-
The acute effect of high-dose supplemental oxygen on haemodynamics assessed by echocardiography in patients with pulmonary vascular disease living in Quito at 2850 m: a randomized, single-blind, placebo-controlled crossover trial.Eur Heart J Open. 2024 Dec 2;4(6):oeae097. doi: 10.1093/ehjopen/oeae097. eCollection 2024 Nov. Eur Heart J Open. 2024. PMID: 39698150 Free PMC article.
-
Acetazolamide for OSA and Central Sleep Apnea: A Comprehensive Systematic Review and Meta-Analysis.Chest. 2020 Dec;158(6):2632-2645. doi: 10.1016/j.chest.2020.06.078. Epub 2020 Aug 5. Chest. 2020. PMID: 32768459 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical